The DMD/MBA program is an integrative, four-year degree that combines business courses with the DMD curricula. Students start their business classes the summer before dentistry school. The remaining ...

Gemma Biotherapeutics ("GEMMABio"), a clinical‑stage, global, genetic medicines company, today announced the presentation of preclinical data supporting candidate declaration for GB703, a novel, ...

Strong Buy on DM1 & DMD clinical progress, BLA timeline, and strong cash runway through 2028. Click for this DYN update.

Students are eligible to enter the DMD/MPH program after the second year of predoctoral studies in dentistry. The combined program will allow students who have demonstrated academic excellence to earn ...

Navigating IT support at the School of Dentistry can be complex, but we're here to help. This guide will direct you to the appropriate team for your specific IT needs, whether it's related to clinical ...

Keros Therapeutics, Inc. KROS is pushing its lead asset, rinvatercept, into neuromuscular disease with Duchenne muscular dystrophy at the front of the line. The company is positioning the program ...

Sarepta Therapeutics says its RNA therapy for Duchenne muscular dystrophy (DMD) could be more effective than its existing drugs, but a dose-escalation study also dug up some new—and serious—adverse ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.